PRPO · Precipio Inc

-

Please sign in to comment on PRPO

1 Comment

Admin

4 years, 1 month ago

Precipio, Inc is currently in a long term uptrend where the price is trading 17.6% above its 200 day moving average.

From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.

Precipio, Inc's total revenue rose by 344.8% to $3M since the same quarter in the previous year.

Its net income has increased by 100.0% to $-2K since the same quarter in the previous year.

Finally, its free cash flow grew by 31.0% to $-1M since the same quarter in the previous year.

Based on the above factors, Precipio, Inc gets an overall score of 5/5.

Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Diagnostics & Research
ISIN	US74019L5030

Target Price	19
Beta	1.12
Market Cap	11M
PE Ratio	None
Dividend Yield	None

ABOUT

Precipio Inc

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

PRPO · Precipio Inc

-

Precipio Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Precipio Inc using a moving average strategy